secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2023-07-18T23:59:59+00:00
Accession:  0001437749-23-020093
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex signs exclusive license for diabetes gene therapy with University of Pittsburgh
--------------------------------------------------------------------------------

- Exclusive worldwide license for gene therapy using MafB promoter to drive Pdx1 and MafA for Type 1 and Type 2 diabetes.
- Preclinical NHP data showed statistically significant decreases in insulin requirements (p<0.001), increased c-peptide (p<0.05), improved glucose tolerance.
- Milestone payments up to ~$4.225M plus royalties; technology co-developed by Dr. George Gittes.
- Expands existing diabetes gene therapy portfolio; AAV vector delivered via endoscopy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774923020093/0001437749-23-020093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774923020093/gnpx20230703_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-020093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer